BS
OCUL icon

Banco Santander’s Ocular Therapeutix OCUL Stock Holding History

Banco Santander’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-184,048
Closed -$1.71M – 507
2025
Q2 		$1.71M Hold
184,048
– – 0.02% 282
2025
Q1 		$1.35M Buy
184,048
+32,941
+22% +$253K 0.01% 298
2024
Q4 		$1.29M Sell
151,107
-21,124
-12% -$206K 0.02% 263
2024
Q3 		$1.5M Sell
172,231
-205,137
-54% -$1.69M 0.02% 250
2024
Q2 		$2.58M Buy
377,368
+169,172
+81% +$1.04M 0.03% 209
2024
Q1 		$1.89M Sell
208,196
-332,280
-61% -$2.36M 0.02% 232
2023
Q4 		$2.41M Buy
540,476
+143,033
+36% +$423K 0.03% 220
2023
Q3 		$1.25M Hold
397,443
– – 0.02% 273
2023
Q2 		$2.05M Buy
397,443
+129,554
+48% +$770K 0.03% 223
2023
Q1 		$1.41M Sell
267,889
-60,425
-18% -$287K 0.02% 198
2022
Q4 		$923K Sell
328,314
-24,497
-7% -$81.1K 0.01% 245
2022
Q3 		$1.46M Sell
352,811
-203,073
-37% -$1.02M 0.02% 214
2022
Q2 		$2.23M Buy
+555,884
New +$2.1M 0.03% 205

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Banco Santander's OCUL Position: Q3 2025 in Review

Banco Santander sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 184,048 shares — an estimated $1.71M sold.

Banco Santander first reported a position in OCUL in Q2 2022 and held it in 13 quarters. The position peaked at $2.58M in Q2 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Banco Santander reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • Banco Santander sold 184,048 Ocular Therapeutix shares in Q3 2025, an estimated $1.71M.
  • Banco Santander first reported a position in Ocular Therapeutix in Q2 2022 and held it in 13 quarters.
  • Banco Santander's Ocular Therapeutix position peaked at $2.58M in Q2 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Banco Santander's 13F filing for Q3 2025, filed 12 Nov 2025.